Colin A. Kretz

Dr. Colin A. Kretz


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 September 2022 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
VDVeronica DeYoung
Veronica DeYoung
KSKanwal Singh
Kanwal Singh
CKColin A. Kretz
Colin A. Kretz
Recombinant ADAMTS13 is currently undergoing clinical trials as a treatment for hereditary thrombotic thrombocytopenic purpura, a lethal microvascular condition resulting from ADAMTS13 deficiency. Preclinical studies have also demonstrated its efficacy in treating arterial thrombosis and inflammation without causing bleeding, suggesting that recombinant ADAMTS13 may have broad applicability as an antithrombotic agent. Despite this progress, we currently do not understand the mechanisms that regulate ADAMTS13 activity in vivo. ADAMTS13 evades canonical means of protease regulation because it is secreted as an active enzyme and has a long half‐life in circulation, suggesting that it is not inhibited by natural protease inhibitors. Although shear can spatially and temporally activate von Willebrand factor to capture circulating platelets, it is also required for cleavage by ADAMTS13. Therefore, spatial and temporal regulation of ADAMTS13 activity may be required to stabilize von Willebrand factor‐platelet strings at sites of vascular injury. This review outlines potential mechanisms that regulate ADAMTS13 in vivo including shear‐dependency, local inactivation, and biochemical and structural regulation of substrate binding. Recently published structural data of ADAMTS13 is discussed, which may help to generate novel hypotheses for future research.

17 July 2014 in Blood
Verified
Journal Article
Open access
PDF file
AYAndrew Yee
Andrew Yee
RGRobert D. Gildersleeve
Robert D. Gildersleeve
SGShufang Gu
Shufang Gu
CKColin A. Kretz
Colin A. Kretz
BMBeth M. McGee
Beth M. McGee
DGDavid Ginsburg
David Ginsburg
Key Points: The D′D3 domains of VWF are sufficient to stabilize FVIII in vivo. The prolongation of VWF D′D3 survival in vivo by Fc fusion elevates FVIII levels in the setting of VWF but not FVIII deficiency.

3 July 2014 in Blood
Verified
Journal Article
Open access
PDF file
YLYang Liu
Yang Liu
CKColin A. Kretz
Colin A. Kretz
MMMorgan L. Maeder
Morgan L. Maeder
CRCatherine E. Richter
Catherine E. Richter
PTPhilip Tsao
Philip Tsao
JSJordan A. Shavit
Jordan A. Shavit
Key Points: Juvenile zebrafish tolerate widespread coagulopathy due to complete ablation of antithrombin III, but develop lethal thrombosis as adults. In vivo structure/function analysis of antithrombin III in zebrafish reveals limited roles for heparin-binding and anti-IXa/Xa activity.

20 August 2015 in Blood
Verified
Journal Article
Closed access
PDF file
AYAndrew Yee
Andrew Yee
AOAustin N. Oleskie
Austin N. Oleskie
ADAnne M. Dosey
Anne M. Dosey
CKColin A. Kretz
Colin A. Kretz
RGRobert D. Gildersleeve
Robert D. Gildersleeve
GSGeorgios Skiniotis
Georgios Skiniotis
Binding to the von Willebrand factor (VWF) D′D3 domains protects factor VIII (FVIII) from rapid clearance. We performed single-particle electron microscopy (EM) analysis of negatively stained specimens to examine the architecture of D′D3 alone and in complex with FVIII. The D′D3 dimer ([D′D3]2) comprises 2 antiparallel D3 monomers with flexibly attached protrusions of D′. FVIII-VWF association is primarily established between the FVIII C1 domain and the VWF D′ domain, whereas weaker interactions appear to be mediated between both FVIII C domains and the VWF D3 core. Modeling the FVIII structure into the three-dimensional EM reconstructions of [D′D3]2-FVIII ternary and quaternary complexes indicates conformational rearrangements of the FVIII C domains compared with their disposition in the unbound state. These results illustrate the cooperative plasticity between VWF and FVIII that coordinate their high-affinity interaction. Key Points The VWF D′ domains are flexibly tethered entities projecting outside antiparallel dimers of the VWF D3 domain. Extensive interactions between the VWF D′ domain and primarily the FVIII C1 domain mediate VWF-FVIII association.

13 December 2013 in Seminars in Thrombosis and Hemostasis
Verified
Journal Article
Closed access
CKColin A. Kretz
Colin A. Kretz
AYAndrew Yee
Andrew Yee
The mechanisms by which von Willebrand factor (VWF) achieves hemostasis lie in its structure. Whereas low-molecular-weight forms have diminished hemostatic potential, ultralarge VWF (ULVWF) in excess is potentially thrombogenic. VWF comprises many subunits, which themselves comprise many repeated domains/assemblies possessing characteristic function(s). Organization of these domains/assemblies into a multimeric structure effectively links and replicates these functions. Each domain/assembly influences the synthesis, assembly, secretion, or hemostatic potential of plasma VWF. The C-terminal CT/CK domain mediates dimerization of VWF subunits in the endoplasmic reticulum, while the N-terminal D1D2 assemblies catalyzes disulfide binding between juxtaposed D3 assemblies in the trans-Golgi, creating multimers. The pH-sensitive domains (A2–CT/CK) allow ULVWF multimers to orderly pack into tubules that unravel upon secretion into the circulation. Hemodynamic forces regulate the conformation of the A2 domain and thus, its accessibility to proteolytic enzyme(s) that regulate VWF's hemostatic potential. Binding to the VWF D'D3 assemblies stabilizes coagulation factor VIII. The VWF A1 and A3 domains facilitate platelet capture onto exposed collagen(s) at sites of vascular injury. Our deeper understanding of VWF provided through the recent growth in VWF structure-function studies may potentially guide novel therapeutics for clotting or bleeding disorders.

4 April 2015 in Current Pathobiology Reports
Verified
Journal Article
Closed access
PDF file
CKColin A. Kretz
Colin A. Kretz
AWAngela C. Weyand
Angela C. Weyand
JSJordan A. Shavit
Jordan A. Shavit